Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Sofetabart Mipitecan · LY-4170156, MBK-103

Antibody-drug conjugate · Cytotoxic, directed at folate receptor alpha (FOLR1) · developed by ELI LILLY &

Phase 3 Most advanced trial

LLY Developer

1 Registered trials

What is Sofetabart Mipitecan?

Sofetabart mipitecan is an antibody-drug conjugate made of a humanized, Fc-silenced IgG1 antibody that binds folate receptor alpha on tumor cells, linked to the topoisomerase I inhibitor exatecan. After binding and uptake, the linker is cleaved and exatecan is released to cause DNA strand breaks and tumor cell death. It is being studied in ovarian, fallopian tube and peritoneal neoplasms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: LY-4170156, MBK-103, Sofe-M
Drug type: Antibody-drug conjugate
Targets: folate receptor alpha (FOLR1)
Mechanism: Cytotoxic, directed at folate receptor alpha (FOLR1)
Pathways: DNA replication inhibition, cell cycle arrest, apoptosis, bystander effect on neighboring tumor cells
Therapy area: Oncology
Developer: ELI LILLY & (LLY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: E9VWP79J9B

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07213804	Phase 3	Ovarian Neoplasms	Recruiting	LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fallopian Tube NeoplasmsNeoplasm MetastasisOvarian NeoplasmsPeritoneal Neoplasms

Other drugs acting on FOLR1

ABBV-901 Phase 1 Opugotamig Olatansine Phase 2 Torvutatug Samrotecan Phase 1 ZW191 Phase 1

More from ELI LILLY &

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3

Sources

NCI Thesaurus

Updated Oct 11, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind Sofetabart Mipitecan

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z